Nymox Pharmaceutical Corp. Company Profile (NASDAQ:NYMX)

About Nymox Pharmaceutical Corp.

Nymox Pharmaceutical Corp. logo

Nymox Pharmaceutical Corporation, formerly Corporation Pharmaceutique Nymox, is a biopharmaceutical company. The Company is focused on developing its drug candidate, NX-1207, for the treatment of benign prostatic hyperplasia (BPH) and the treatment of low-grade localized prostate cancer. The Company markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. The Company also has a patent portfolio covering its marketed products, its investigational drug, as well as other therapeutic and diagnostic indications. The Company also has the United States and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The Company's subsidiaries include Nymox Corporation and Serex, Inc. Nymox Corporation conducts research and development, while Serex conducts research and development, and manufacturing for NicAlert and TobacAlert.

Industry, Sector and Symbol:

Sector: Medical
Industry: Diagnostic Substances
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: NYMX
CUSIP:

Key Metrics:

Previous Close: $3.23
50 Day Moving Average: $3.15
200 Day Moving Average: $2.81
52-Week Range: $1.62 - $5.79
Trailing P/E Ratio: N/A
P/E Growth: 0.00
Market Cap: $149.05M
Outstanding Shares: 46,145,000
Beta: 0.72

Profitability:

Net Margins: -6,774.20%
Return on Assets: -3,038.71%

Debt:

Debt-to-Equity Ratio: -0.39%
Current Ratio: 0.29%
Quick Ratio: 0.27%

Additional Links:

Companies Related to Nymox Pharmaceutical Corp.:

Consensus Ratings for Nymox Pharmaceutical Corp. (NASDAQ:NYMX) (?)

Ratings Breakdown:	No ratings tracked in the last 12 months.
Consensus Rating:	N/A (Score: NaN)
Consensus Price Target:	N/A

Analysts' Ratings History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)

Show:

No equities research coverage for this company has been tracked by MarketBeat.com

Earnings History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/14/2014	Q314		($0.02)			View	N/A
5/15/2014	Q114		$0.07	$0.18 million	$0.08 million	View	N/A
3/14/2014		($0.06)	($0.04)			View	N/A
11/13/2013	Q3		($0.03)			View	N/A
5/15/2013	Q1 2013	($0.05)	($0.03)	$0.78 million	$0.18 million	View	N/A
11/14/2012	Q312	($0.06)	($0.04)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)

Insider Ownership Percentage: 54.00%
Institutional Ownership Percentage: 1.43%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
8/10/2016	James George Robinson	Director	Buy	500	$2.47	$1,235.00
8/4/2016	James George Robinson	Director	Buy	7,000	$3.41	$23,870.00
7/29/2016	James George Robinson	Director	Buy	22,500	$3.86	$86,850.00
7/20/2016	James George Robinson	Director	Buy	10,000	$3.33	$33,300.00
7/7/2016	James George Robinson	Director	Buy	20,000	$3.28	$65,600.00
6/29/2016	James George Robinson	Director	Buy	17,500	$3.53	$61,775.00
6/24/2016	James George Robinson	Director	Buy	22,500	$2.97	$66,825.00
5/13/2016	James George Robinson	Director	Buy	28,010	$2.31	$64,703.10
5/3/2016	James George Robinson	Director	Buy	6,990	$2.36	$16,496.40
4/29/2016	James George Robinson	Director	Buy	15,000	$2.27	$34,050.00
4/15/2016	James George Robinson	Director	Buy	39,500	$2.39	$94,405.00
4/1/2016	James George Robinson	Director	Buy	20,500	$2.40	$49,200.00
3/24/2016	James George Robinson	Director	Buy	40,000	$2.29	$91,600.00
1/12/2016	James George Robinson	Director	Buy	20,000	$2.44	$48,800.00
1/8/2016	James George Robinson	Director	Buy	95,000	$2.90	$275,500.00
12/30/2015	James George Robinson	Director	Buy	5,000	$3.38	$16,900.00
12/29/2015	James George Robinson	Director	Buy	14,000	$3.55	$49,700.00
12/28/2015	James George Robinson	Director	Buy	6,000	$3.79	$22,740.00
12/23/2015	James George Robinson	Director	Buy	29,854	$3.54	$105,683.16
12/18/2015	James George Robinson	Director	Buy	63,334	$3.56	$225,469.04
12/11/2015	James George Robinson	Director	Buy	46,812	$3.51	$164,310.12
12/4/2015	James George Robinson	Director	Buy	110,000	$3.44	$378,400.00
9/3/2015	James George Robinson	Director	Buy	100,000	$2.25	$225,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Nymox Pharmaceutical Corp. (NASDAQ:NYMX)

Date	Headline
	Nymox Pharmaceutical Corporation (NASDAQ:NYMX): Ignore The Shorts - Street Register (NASDAQ:NYMX) streetregister.com - September 29 at 11:40 AM
	Stock Turning Lower in Trade: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Post News (NASDAQ:NYMX) www.kentuckypostnews.com - September 14 at 6:40 PM
	$NOK & $NYMX - Nokia Corp (ADR) (NYSE:NOK) & Nymox Pharmaceutical Corporation (NASDAQ:NYMX) News Recap - Money News (NASDAQ:NYMX) www.newsismoney.com - September 14 at 6:40 PM
	Is Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Overbought After Prostate Drug Hype? - Journal Transcript (NASDAQ:NYMX) www.journaltranscript.com - September 14 at 6:40 PM
	U.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.41% (NASDAQ:NYMX) www.investing.com - September 14 at 10:48 AM
	Nasdaq Index Recovery Rally Stalls as Tech Stocks Hang on By a Thread (NASDAQ:NYMX) www.economiccalendar.com - September 14 at 10:48 AM
	Nymox Pharmaceutical Corp. (NYMX) Is Suring In Early Trade (NASDAQ:NYMX) www.rttnews.com - September 14 at 10:48 AM
	Getting a Closer Look at Shares of Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Duncan Research (NASDAQ:NYMX) www.duncanindependent.com - September 13 at 11:25 AM
	Now Available: Nymox Pharmaceutical Corporation (NYMX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile (NASDAQ:NYMX) www.live-pr.com - September 2 at 11:22 AM
	Stock Down in Trading Session: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) - Post News (NASDAQ:NYMX) www.kentuckypostnews.com - September 1 at 6:29 PM
	Nymox Pharmaceutical Corporation's (NYMX): Stock on the Move - Hot Stocks Point (NASDAQ:NYMX) www.hotstockspoint.com - September 1 at 6:29 PM
	Nymox Pharmaceutical : New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show (NASDAQ:NYMX) www.4-traders.com - August 30 at 9:52 AM
	Nymox Pharmaceutical Corporation (NYMX) Puts Popular Despite Drug Data (NASDAQ:NYMX) www.schaeffersresearch.com - August 30 at 9:52 AM
	Nymox Pharmaceutical Corporation (NYMX) Puts Popular Despite Drug Data - Schaeffers Research (blog) (NASDAQ:NYMX) www.schaeffersresearch.com - August 29 at 6:22 PM
	Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show (NASDAQ:NYMX) finance.yahoo.com - August 29 at 11:04 AM
	Nymox Pharmaceutical Corporation (NASDAQ:NYMX): Ignore The Shorts (NASDAQ:NYMX) streetregister.com - August 27 at 5:56 PM
	Nymox Pharmaceutical Corporation (NYMX) Has More Upside Potential, Even After Gains - Insider Monkey (blog) (NASDAQ:NYMX) www.insidermonkey.com - August 27 at 10:52 AM
	Yesterday Trading Recap: Nymox Pharmaceutical Corporation's (NYMX) (NASDAQ:NYMX) myhealthbowl.com - August 26 at 6:20 PM
	Jabbing a Needle in the Overinflated Nymox Prostate Drug Hype (NASDAQ:NYMX) www.thestreet.com - August 26 at 6:20 PM
	Nymox Pharmaceutical (NYMX) Leaps on Study Results (NASDAQ:NYMX) www.baystreet.ca - August 25 at 6:33 PM
	Anti-Prostate Cancer Drug Boosts Nymox Pharma (NYMX); Viveve Medical (VIVE) Moves Into Positive Territory (NASDAQ:NYMX) galaxystocks.com - August 25 at 6:33 PM
	Nymox Pharmaceutical Corporation (NYMX) Has More Upside Potential, Even After Gains (NASDAQ:NYMX) feedproxy.google.com - August 25 at 2:51 PM
	18 Stocks Moving In Thursday's Pre-Market Session - Benzinga (NASDAQ:NYMX) www.benzinga.com - August 25 at 11:43 AM
	Nymox Pharma (NYMX) Stock: Skyrocketing on Positive Study Results - Modest Money (press release) (blog) (NASDAQ:NYMX) www.modestmoney.com - August 25 at 11:43 AM
	Why Nymox Pharma (NYMX) Closed the Day Up 83% (NASDAQ:NYMX) finance.yahoo.com - August 25 at 11:43 AM
	Nymox Pharma (NYMX) Announces Successful, Long-Term Fexapotide Phase 3 Data in Prostate Cancer (NASDAQ:NYMX) www.streetinsider.com - August 24 at 6:20 PM
	Investor News: Nymox Pharmaceutical Corporation (NASDAQ:NYMX) faces Investigation over potential Violations of Securities Laws (NASDAQ:NYMX) www.groundreport.com - August 24 at 6:20 PM
	Nymox Pharma (NYMX) Stock: Skyrocketing on Positive Study Results (NASDAQ:NYMX) www.modestmoney.com - August 24 at 6:20 PM
	12:19 pm Nymox Pharma announces results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide (NASDAQ:NYMX) finance.yahoo.com - August 24 at 6:20 PM
	Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery (NASDAQ:NYMX) finance.yahoo.com - August 24 at 6:20 PM
	Nymox Pharmaceuticals (NYMX) Stock Surges on Long-Term Prostate Drug Trial Success (NASDAQ:NYMX) www.thestreet.com - August 24 at 6:20 PM
	Nymox reports 2Q loss (NASDAQ:NYMX) sg.finance.yahoo.com - August 22 at 11:08 AM
	HC Stocks Indications: CVS Health Corp (NYSE:CVS), Nymox ... - share market updates (press release) (NASDAQ:NYMX) sharemarketupdates.com - August 20 at 6:14 PM
	Nymox Pharma (NYMX) Closes $2.24M Worth of Common Stock Private Placements - StreetInsider.com (NASDAQ:NYMX) www.streetinsider.com - August 18 at 9:39 AM
	Nymox Pharmaceutical Corporation's (NYMX): Stock's Financial Statistics - Hot Stocks Point (NASDAQ:NYMX) www.hotstockspoint.com - August 18 at 9:39 AM
	Nymox Pharma (NYMX) Closes $2.24M Worth of Common Stock Private Placements (NASDAQ:NYMX) www.streetinsider.com - August 17 at 6:51 PM
	Nymox Pharmaceutical Corporation (NASDAQ:NYMX) Under Investigation for Investors (NASDAQ:NYMX) www.sbwire.com - August 17 at 6:51 PM
	Nymox Pharmaceutical : Announces Prostate Drug Progress (NASDAQ:NYMX) www.4-traders.com - August 17 at 6:51 PM
	Nymox Announces Private Placements of $2.24 Million (NASDAQ:NYMX) www.publicnow.com - August 17 at 6:51 PM
	Healthcare Stock Round up: Nymox Pharmaceutical Corporation's (NYMX) - Hot Stocks Point (NASDAQ:NYMX) www.hotstockspoint.com - August 15 at 6:54 PM
	Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals ... - PR Newswire (press release) (NASDAQ:NYMX) www.prnewswire.com - August 13 at 9:29 AM
	Healthcare Stocks In The News: Kura Oncology Inc (NASDAQ:KURA), Nymox Pharmaceutical Corporation (NASDAQ ... - NYSE Journal (press release) (NASDAQ:NYMX) stockznews.com - August 12 at 9:47 AM
	Healthcare Volatile Stocks: Nymox Pharmaceutical Corporation (NASDAQ:NYMX), Kura Oncology, Inc. (NASDAQ ... - KC Register (NASDAQ:NYMX) www.kcregister.com - August 12 at 9:47 AM
	Stocks Attracts Frontline Trades- Medtronic (NYSE:MDT), Nymox Pharmaceutical (NASDAQ:NYMX), Radian Group ... - Seneca Globe (NASDAQ:NYMX) www.senecaglobe.com - August 12 at 9:47 AM
	IMPORTANT INVESTOR NOTICE: Lundin Law PC... (NASDAQ:NYMX) www.benzinga.com - August 11 at 7:03 PM
	Nymox Announces Prostate Drug Progress (NASDAQ:NYMX) globenewswire.com - August 11 at 7:03 PM
	Nymox readies marketing application for BPH drug fexapotide; shares up 31% (NASDAQ:NYMX) seekingalpha.com - August 11 at 7:03 PM
	Nymox Pharma (NYMX) Announces Major Fexapotide Development Progress (NASDAQ:NYMX) www.streetinsider.com - August 11 at 7:03 PM
	Nymox Pharmaceuticals (NYMX) Stock Surges on Prostate Drug Progress (NASDAQ:NYMX) www.thestreet.com - August 11 at 7:03 PM
	NASDAQ Index Near Upper Bollinger Band, At Risk of Turning Downward Eventually (NASDAQ:NYMX) www.economiccalendar.com - August 11 at 9:48 AM